Ipca Labs gets 3 USFDA observations for Piparia facility

Published On 2023-04-27 05:45 GMT   |   Update On 2023-04-27 05:45 GMT
Advertisement

Mumbai: Ipca Laboratories has recently announced that the US Food and Drug Administration (USFDA) has issued a Form 483 with 3 observations at the conclusion of the inspection at the company's Piparia facility.

The inspection was held from 18 April, 2023 to 26 April, 2023

"This is to inform you that the US FDA conducted the inspection of the Company's formulations manufacturing unit situated at Piparia (Silvassa) from 18th April, 2023 to 26th April, 2023," the company informed in a BSE filing.
Advertisement

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

"The Company will submit its comprehensive response on these observations to the US FDA within the stipulated time and shall work closely with the agency to resolve these issues at the earliest," 
Ipca further informed.
"The Company takes the quality and compliance issues with utmost importance and remains committed to maintain the highest standards of quality and compliance across all its facilities," Ipca added.

Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in MumbaiThe company was founded by group of businessmen and medical professionals in 1949. It produces theobromine, acetyl thiophene, and p-bromotoluene as active pharmaceutical ingredients (APIs). Ipca sells these APIs and their intermediates globally. Ipca is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments.

Read also: Ipca Labs buys 13.09 percent stake in Trophic Wellness for Rs 21.20 crore

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News